A ‘More Decisive’ Response: Ozempic, City Policy, and the Cost of Care

The city’s decision to cover Ozempic prescriptions has ignited a debate about public health spending, political accountability, and the urgent need for drug affordability. Globo? Let’s examine the facts that frame this issue. 1. **What Is Ozempic and Why Is It Expensive?** - Ozempic is a brand-name GLP‑1 medication used for weight management and also prescribed for diabetes. In the United States, the monthly cost for uninsured adults can exceed US$1,000. - The high price reflects a patent monopoly that has kept competing versions out of the market for years. 2. **The Canadian Generic Breakthrough** - Canada became the first G7 country to approve generic semaglutide in June 2026. Two manufacturers—Dr Reddy’s and Apotex—now offer the drug at less than a third of the cost of the brand name. - The approval forced Novo Nordisk to lower prices for Ozempic and Wegovy in Canada, and the generic itself is expected to make the medication far more affordable for Canadians. 3. **Implications for U.S. Patients** - In the United States, generics for semaglutide are not expected to appear until 2032 when the main patent expires. US patent laws allow extensions that prevent competition for decades. - Low‑cost alternatives are currently unavailable, leaving many patients—particularly those with limited insurance coverage—unable to access GLP‑1 drugs. 4. **George and Jill Biden, and the Politics of Misinformation** - An article in *Reason.com* highlighted false statements attributed to Jill Biden, describing the situation as “the forcible? ”, casting doubt on the presidency’s handling of the crisis. - The dismissal of credible data can hinder bipartisan efforts that might otherwise push for drug price reform. 5. **The City’s Policy and Fiscal Duty** - Covering Ozempic for city workers demonstrates a commitment to preventive health. However, the city must account for the substantial cost per prescription. - Policymakers must weigh the immediate benefit to staff against long‑term public health savings—if the medication reduces early‑stage diabetes, in particular. 6. **The Bigger Picture: Drug Reform and Accountability** - The case of Ozempic illustrates a broader systemic problem: that drug patents and price controls lag behind real-world needs. - There are calls from public health experts for a re‑evaluation of how patent extensions affect drug access. One major player, the Initiative for Medicines, Access & Knowledge (I‑MAK), calls for “Golden‑Egg” reforms. 7. **Conclusion** - The city government’s coverage of Ozempic is a small but symbolic step toward tackling drug affordability. Yet it also underscores the necessity for larger policy shifts, such as federal patent reform and mechanisms that allow generics to enter the U.S. market sooner. - Until the national debate over drug pricing and intellectual property takes shape, city leaders will continue to navigate the tension between fiscal restraint and the pressing health needs of their constituents. References are based solely on the provided articles: a commentary on political dynamics and the weight of public health policy, and detailed reporting on Canada’s approval of generic Ozempic, its impact on pricing, and US drug patent restrictions.